These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 35581611)

  • 41. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
    Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
    Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
    Iacovelli R; Ciccarese C; Maruzzo M; Atzori F; Galli L; Scagliarini S; Massari F; Verzoni E; Cannella A; Maratta MG; Caserta C; Bimbatti D; Deppieri FM; Dessi M; Paolieri F; Riccardi F; Bracarda S; De Giorgi U; Basso U; Tortora G; Procopio G
    Clin Genitourin Cancer; 2022 Oct; 20(5):498.e1-498.e9. PubMed ID: 35768316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
    Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
    Hashimoto M; Nakayama T; Fujimoto S; Inoguchi S; Nishimoto M; Kikuchi T; Adomi S; Banno E; De Velasco MA; Saito Y; Shimizu N; Mori Y; Minami T; Fujita K; Nozawa M; Nose K; Yoshimura K; Uemura H
    Anticancer Drugs; 2022 Jan; 33(1):e818-e821. PubMed ID: 34486537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
    Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
    Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
    Kojima T; Kato R; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Nakaigawa N; Sugino Y; Hamamoto S; Ito H; Murakami H; Obara W
    Jpn J Clin Oncol; 2022 Nov; 52(11):1345-1352. PubMed ID: 35920793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
    Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W
    Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Negishi T; Nakagawa T; Nishiyama N; Kitamura H; Okajima E; Furubayashi N; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Nakamura M
    Jpn J Clin Oncol; 2022 Dec; 52(12):1430-1435. PubMed ID: 36093731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
    Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
    Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [INTERSTITIAL NEPHRITIS CAUSED BY IPILIMUMAB AND NIVOLUMAB COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A CASE REPORT].
    Ishii M; Takezawa K; Imamura R; Fukuhara S; Fujita K; Uemura M; Kiuchi H; Nonomura N
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):109-112. PubMed ID: 35444079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
    Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
    J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
    Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.